Trials / Completed
CompletedNCT04204265
MONOVISC for Shoulder Joint Pain Relief Due to Osteoarthritis
A Prospective Study of a Single Injection Cross-linked Sodium Hyaluronate (MONOVISC) to Provide Symptomatic Relief of Osteoarthritis of Shoulder Joint
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Anika Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Obtain real world, post market data to confirm the clinical improvement and safety in patients treated with a single injection of MONOVISC for the symptomatic relief of osteoarthritis in the shoulder joint.
Detailed description
The goal of this study is to demonstrate the clinical improvement and safety in patients treated with MONOVISC for shoulder osteoarthritis. Specifically, this study will provide confirmation to the effectiveness and safety of MONOVISC at relieving shoulder joint pain to 6 months post-treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Monovisc | A chemically cross-linked sodium hyaluronate supplied as a 4 mL unit dose in a 5 mL glass syringe. |
Timeline
- Start date
- 2019-12-17
- Primary completion
- 2021-02-26
- Completion
- 2021-03-30
- First posted
- 2019-12-18
- Last updated
- 2025-01-28
- Results posted
- 2025-01-28
Locations
4 sites across 2 countries: Czechia, Poland
Source: ClinicalTrials.gov record NCT04204265. Inclusion in this directory is not an endorsement.